困難梭狀芽孢桿菌診斷市場：按診斷測試、最終用戶和地區分類

2026年困難梭狀芽孢桿菌診斷市場規模預計為11.188億美元，預計2033年將達到18.521億美元。預計2026年至2033年，該市場將以7.5%的複合年成長率成長。

困難梭狀芽孢桿菌傳染病(CDI) 的診斷通常採用傳統的臨床實驗室方法，但目前也有快速照護現場診斷檢測方法，可顯著節省時間和成本。困難梭狀芽孢桿菌傳染病是一種細菌性疾病，可表現出多種症狀，包括腹瀉、噁心和結腸發炎。此外，抗生素會殺死體內有益菌，促進困難梭狀芽孢桿菌的生長，因此經常使用抗生素也可能導致困難梭狀芽孢桿菌傳染病。水樣腹瀉、脫水、發燒、噁心、食慾不振和體重減輕是困難梭狀芽孢桿菌傳染病的典型徵兆。用於檢測 CDI 的診斷方法包括針對毒素 A/B的酵素免疫分析法(EIA)。然而，由於其靈敏度較低，這些方法不再被視為主要的診斷方法。其他檢測方法包括麩胺酸脫氫酶酵素免疫分析法和基於聚合酵素鏈鎖反應(PCR) 的分子檢測。此外，等溫擴增技術也已獲得美國食品藥物管理局(FDA) 的核准，可作為艱難梭菌感染 (CDI) 的診斷方法。 Cepheid、BD Diagnostics、DiaSorin、Abbott Laboratories、Thermo Fisher Diagnostics 和 Luminex Corporation 等製造商均提供先進的困難梭狀芽孢桿菌傳染病診斷測試。例如，Cepheid 的 GeneXpert 測試和 Luminex Corporation 的 Nanosphere Verigene SP 測試均具有高靈敏度和快速的困難梭狀芽孢桿菌傳染病結果。

市場動態

困難梭狀芽孢桿菌傳染病日益普遍、即時聚合酵素鏈鎖反應(RT-PCR) 等精準先進診斷技術的普及，以及甲硝唑等學名藥抗生素學名藥的出現，預計將推動困難梭狀芽孢桿菌診斷和治療市場在預測期內的成長。此外，許多組織和生產商正致力於提高大眾對困難梭狀芽孢桿菌傳染病及其嚴重性的認知。例如，2018 年 3 月，艱難梭菌基金會授予製藥公司 CutisPharma, Inc. “做出貢獻獎”，以表彰其在提高公眾意識和拓展治療選擇方面所做的貢獻。

本次調查的主要特點。

• 本報告對全球困難梭狀芽孢桿菌診斷市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模和復合年成長率（%）。
• 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數對全球困難梭狀芽孢桿菌診斷市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。 ¹
• 透過各種用於分析全球困難梭狀芽孢桿菌診斷市場的策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機遇
• 影響分析
• 主要亮點
• 近期產品核可上市
• 流行病學
• 市場趨勢
• 波特的分析
• PEST分析
• 技術進步
• 法規環境

第4章 全球困難梭狀芽孢桿菌診斷市場：依診斷檢驗類型分類，2020-2033年

• 概述
• 酵素免疫分析法
• 即時聚合酵素鏈鎖反應（RT-PCR）
• 核酸增幅檢查（NAAT）
• 糞便檢驗
• 驗血
• 大腸鏡檢查或乙狀結腸鏡檢查
• 其他

第5章 全球困難梭狀芽孢桿菌診斷市場：依最終使用者分類，2020-2033年

• 概述
• 醫院
• 診斷中心
• 專科診所
• 其他

第6章 全球困難梭狀芽孢桿菌診斷市場：依地區分類，2020-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific
• Merck &Co., Inc.
• Pfizer, Inc.
• Actelion Pharmaceuticals, Inc.
• Abbott Laboratories
• Trinity Biotech Plc
• Summit Therapeutics
• Sanofi SA
• Novartis AG
• AstraZeneca Plc

第8章

• 調查方法
• 關於本公司

Clostridium Difficile Diagnostics Market is estimated to be valued at USD 1,118.8 Mn in 2026 and is expected to reach USD 1,852.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.

Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Clostridium difficile is a disease caused by bacteria. The illness manifests as a variety of symptoms, such as diarrhea, nausea, and colon inflammation. Furthermore, since antibiotics kill healthy bacteria in the body and promote the growth of C. difficile bacteria, they are also responsible for clostridium difficile infection when taken frequently. Watery diarrhoea, dehydration, fever, nausea, loss of appetite, and weight loss are typical signs of clostridium difficile infection. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.

Market Dynamics

Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its "Making a Difference" award to CutisPharma, Inc.-a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.

Key features of the study

• This report provides an in-depth analysis of the global clostridium difficile diagnostics market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global clostridium difficile diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Clostridium Difficile Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Clostridium Difficile Diagnostics market

Clostridium Difficile Diagnostics Market Segmentation

• By Diagnostic Test (Revenue, USD Mn, 2020 - 2033)
  • Enzyme Immunoassays
  • Real-Time Polymerase Chain Reaction (RT-PCR)
  • Nucleic Amplification Tests (NAAT)
  • Stool Test
  • GDH Antigen Test
  • Toxin A and B Test
  • Blood Test
  • Colonoscopy or Sigmoidoscopy
  • Others
• By End User Insights (Revenue, USD Mn, 2020 - 2033)
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Others
• By Region Insights (Revenue, USD Mn, 2020 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Hoffmann-La Roche Ltd,
  • Thermo Fisher Scientific
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Actelion Pharmaceuticals, Inc.
  • Abbott Laboratories
  • Trinity Biotech Plc.
  • Summit Therapeutics
  • Sanofi S.A.
  • Novartis AG
  • AstraZeneca Plc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Diagnostic Test
  • Market Snapshot, By End User
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Highlights
• Recent Product Approvals/Launch
• Epidemiology
• Market Trends
• Porter's Analysis
• PEST Analysis
• Technology Advancement
• Regulatory Scenario

4. Global Clostridium Difficile Diagnostics Market, By Diagnostic Test, 2020-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2020-2033
  • Segment Trends
• Enzyme Immunoassays
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Real-Time Polymerase Chain Reaction (RT-PCR)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Nucleic Amplification Tests (NAAT)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Stool Test
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
    • GDH Antigen Test
    • Toxin A and B Test
• Blood Test
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Colonoscopy or Sigmoidoscopy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Clostridium Difficile Diagnostics Market, By End User, 2020-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2020-2033
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Diagnostic Centers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Clostridium Difficile Diagnostics Market, By Region, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Test, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• F. Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Actelion Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Trinity Biotech Plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Summit Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca Plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

8. Section

• Research Methodology
• About Us